

41 (11)

J Rheumatol 2014;41;2091-2336  
<http://www.jrheum.org/content/41/11.citation>

1. Sign up for TOCs and other alerts  
<http://www.jrheum.org/alerts>
2. Information on Subscriptions  
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints  
[http://jrheum.com/reprints\\_permissions](http://jrheum.com/reprints_permissions)

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

# The Journal of Rheumatology

VOLUME 41: NO. 11

jrheum.org

NOVEMBER 2014

## Editorials

- Something Old, Something New: Biomarkers in Rheumatoid Arthritis** *F. Pratesi, P. Migliorini* . . . . . 2091
- Cardiovascular Events in Early Rheumatoid Arthritis — Role of Tumor Necrosis Factor Inhibition** *L. Ljung* . . . . . 2094
- Law of the Vital Few: Choosing Variables of Disease Activity in Rheumatoid Arthritis**  
*B. Dumitru, M. Buch, E.M. Vital* . . . . . 2097
- Still Trying to Understand Methotrexate**  
*J.M. Kremer* . . . . . 2099
- Human and Viral microRNA Expression in Sjögren Syndrome** *A.P. Cotrim, I. Alevizos* . . . . . 2102

## Articles

- Serum 14-3-3 $\eta$  is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with RA** *W.P. Maksymowych, S.J. Naides, V. Bykerk, K.A. Siminovitch, D. van Schaardenburg, M. Boers, et al* . . . . . 2104
- A Multibiomarker Disease Activity Score for RA Predicts Radiographic Joint Damage in the BeSt Study**  
*I.M. Markusse, L. Dirven, M. van den Broek, C. Bijkerk, K.H. Han, H.K. Ronday, et al* . . . . . 2114
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with RA with an Inadequate Response to a Tumor Necrosis Factor- $\alpha$  Antagonist** *M.C. Genovese, D. van der Heijde, E.C. Keystone, A.J. Spindler, C. Benhamou, A. Kavanaugh, et al* . . . . . 2120
- Tumor Necrosis Factor- $\alpha$  Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early RA: A Nested Case-control Study** *R.J. Desai, J.K. Rao, R.A. Hansen, G. Fang, M. Maciejewski, J. Farley* . . . . . 2129
- Coronary and Abdominal Aorta Calcification in RA: Relationships with Traditional Cardiovascular Risk Factors, Disease Characteristics, and Concomitant Treatments** *J. Paccou, C. Renard, S. Liabeuf, S. Kamel, P. Fardellone, Z.A. Massy, et al* . . . . . 2137

- Detection of Subclinical Synovitis with Macrophage Targeting and Positron Emission Tomography in Patients with RA without Clinical Arthritis** *Y.Y.J. Gent, N. Ahmadi, A.E. Voskuyl, N. Hoetjes, C. van Kuijk, K. Britsemmer, et al* . . . . . 2145
- Patients with RA in Clinical Remission Manifest Persistent Joint Inflammation on Histology and Imaging Studies**  
*A. Anandarajah, R. Thiele, E. Giampoli, J. Monu, G-S. Seo, C. Feng, et al* . . . . . 2153
- Earlier Time to Remission Predicts Sustained Clinical Remission in Early RA — Results from the Canadian Early Arthritis Cohort (CATCH)** *B. Kuriya, J. Xiong, G. Boire, B. Haraoui, C. Hitchon, J. Pope, et al* . . . . . 2161
- Determinants of Erythrocyte Methotrexate Polyglutamate Levels in RA** *E. den Boer, M.C.J.F. de Rotte, S.M.F. Pluijm, S.G. Heil, J.M. Hazes, R. de Jonge* . . . . . 2167
- Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects** *S. Diab, N. Dostrovsky, M. Hudson, S. Taibouet, M.J. Fritzler, M. Baron, et al* . . . . . 2179
- Development of a Modified Hand Mobility in Scleroderma (HAMIS) Test and its Potential as an Outcome Measure in Systemic Sclerosis** *G. Sandqvist, J-Å. Nilsson, D.M. Wuttge, R. Hesselstrand* . . . . . 2186
- The Effect of Male Sex on Survival in Systemic Sclerosis**  
*H. Hussein, P. Lee, C. Chau, S.R. Johnson* . . . . . 2193
- Drug-associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center**  
*F. Ortiz-Sanjuán, R. Blanco, J.L. Hernández, T. Pina, M.C. González-Vela, H. Fernández-Llaca, et al* . . . . . 2201
- MicroRNA Profiling in Chinese Patients with Primary Sjögren Syndrome Reveals Elevated miRNA-181a in Peripheral Blood Mononuclear Cells**  
*L. Peng, W. Ma, F. Yi, Y-J. Yang, W. Lin, H. Chen, et al* . . . . . 2208
- Evaluation of Germinal Center-like Structures and B Cell Clonality in Patients with Primary Sjögren Syndrome with and without Lymphoma** *S.J. Johnsen, E. Berget, M.V. Jonsson, L. Helgeland, R. Omdal, R. Jonsson* . . . . . 2214
- Does Clinical Presentation Predict Response to a Nonsurgical Chronic Disease Management Program for Endstage Hip and Knee OA?** *J.P. Eyles, B.R. Lucas, J.A. Patterson, M.J. Williams, K. Weeks, M. Fransen, et al* . . . . . 2223

 Free online via JRheum Full Release option

Contents continued on page xxii

**Genome wide Gene Expression Analysis of the Posterior Capsule in Patients with OA and Knee Flexion Contracture**  
*T.M. Campbell, G. Trudel, K.K. Wong, O. Laneuville. . . . .* 2232

**Naproxen Effects on Brain Response to Painful Pressure Stimulation in Patients with Knee OA: A Double-blind, Randomized, Placebo-controlled, Single-dose Study**  
*M. Giménez, J. Pujol, Z. Ali, M. López-Solà, O. Contreras-Rodríguez, J. Deus, et al. . . . .* 2240

**Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of OA: 2 Randomized Controlled Trials versus Naproxen**  
*E.F. Ekman, J.S. Gimbel, A.E. Bello, M.D. Smith, D.S. Keller, K.M. Annis, et al. . . . .* 2249

## Pediatric Rheumatology

**What Matters Most for Patients, Parents, and Clinicians in the Course of JIA? A Qualitative Study**  
*J. Guzman, O. Gómez-Ramírez, R. Jurencak, N.J. Shiff, R.A. Berard, C.M. Duffy, et al. . . . .* 2260

## Images in Rheumatology

**Septic Arthritis and Osteomyelitis of the Hip by *Candida albicans***  
*A.K. Taneja, M. Torriani, F.J. Simeone . . . . .* 2270

**Erysipelas-like Erythema in a Patient with Familial Mediterranean Fever**  
*G.S. Breuer, J.D. Taurog . . . . .* 2271

## Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

**Systematic Review of Treatments for PsA: 2014 Update for the GRAPPA**  
*L.C. Coates, A.F. Kavanaugh, C.T. Ritchlin, for the GRAPPA Treatment Guideline Committee. . . . .* 2273

**Drug Therapies for Peripheral Joint Disease in PsA: A Systematic Review**  
*M.L. Acosta Felquer, L.C. Coates, E.R. Soriano, R. Ranza, L.R. Espinoza, P.S. Helliwell, et al. . . . .* 2277

**Updated Guidelines for the Management of Axial Disease in PsA**  
*P. Nash, E. Lubrano, A. Cauli, W.J. Taylor, I. Olivieri, D.D. Gladman. . . . .* 2286

**Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in PsA**  
*A-M. Orbai, J. Weitz, E.L. Siegel, S. Siebert, L.J. Savage, S.Z. Aydin, et al, and the GRAPPA Enthesitis Working Group . . . . .* 2290

**Comprehensive Treatment of Dactylitis in PsA**  
*S. Rose, S. Toloza, W. Bautista-Molano, P.S. Helliwell, on behalf of the GRAPPA Dactylitis Study Group . . . . .* 2295

**Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with PsA: A Systematic Review**  
*W-H. Boehncke, D. Alvarez Martinez, J.A. Solomon, A.B. Gottlieb . . . . .* 2301

**Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group**  
*A.W. Armstrong, W. Tuong, T.J. Love, S. Carneiro, R. Grynszpan, S.S. Lee, et al . . . . .* 2306

**Comprehensive Treatment of PsA: Managing Comorbidities and Extraarticular Manifestations**  
*A. Ogdie, S. Schwartzman, L. Eder, A.B. Maharaj, D. Zisman, S.P. Raychaudhuri, et al . . . . .* 2315

## Correspondence

**Whiplash and Fibromyalgia**  
*D. Kapur . . . . .* 2323

**Reply**  
*G.O. Littlejohn, E.K. Guymmer. . . . .* 2324

## Letters

**Is Structural Damage Evaluation by Traditional Radiographs Still Relevant in RA Clinical Trials?**  
*B. Haraoui, J. Karsh, J.E. Pope, J.C. Thorne, E.C. Keystone. . . . .* 2325

**Lung Function and Survival in Systemic Sclerosis Interstitial Lung Disease**  
*S.S. Ahmed, S.R. Johnson, C. Meaney, C. Chau, T.K. Marras. . . . .* 2326

**Serum Interleukin 18 as a Diagnostic Remission Criterion in Systemic JIA**  
*M. Shimizu, Y. Nakagishi, A. Yoshida, A. Yachie . . . . .* 2328

**Common Variant of PDZK1, Adaptor Protein Gene of Urate Transporters, is Not Associated with Gout**  
*Y. Takada, H. Matsuo, A. Nakayama, M. Sakiyama, A. Hishida, R. Okada, et al. . . . .* 2330

**Methotrexate Use in a Breastfeeding Patient with RA**  
*J.C. Thorne, T. Nadarajah, M. Moretti, S. Ito . . . . .* 2332

**Osteolytic Lesion in PAPA Syndrome Responding to Anti-interleukin 1 Treatment**  
*R. Caorsi, P. Picco, A. Buoncompagni, A. Martini, M. Gattorno. . . . .* 2333

## Book Reviews

**Psoriatic Arthritis (1st Edition)** . . . . . 2335

**Lupus: The Essential Clinician's Guide (2nd Edition)** . . . 2335

**Living with Juvenile Arthritis: A Parent's Guide** . . . . . 2335

## Corrections

**Proliferative Lupus Nephritis and Leukocytoclastic Vasculitis During Treatment with Etanercept**  
*A. Mor, C.O. Bingham 3rd, L. Barisoni, E. Lydon, H.M. Belmont . . . . .* 2336

**Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0**  
*T. Woodworth, D.E. Furst, R. Alten, C.O. Bingham 3rd, D. Yocum, V. Sloan, et al . . . . .* 2336

**Early Increase of Abdominal Adiposity in Patients with Spondyloarthritis Receiving Anti-tumor Necrosis Factor- $\alpha$  Treatment**  
*I. Hmamouchi, C. Roux, S. Paternotte, S. Kolta, M. Dougados, K. Briot . . . . .* 2336

**Meetings in Rheumatology** . . . . . x